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Abstract
In daily clinical practice the diagnosis of lung cancer is often based on cytological
specimens. These cytological samples are increasingly obtained by ultrasound-
guided techniques with fine needle aspirations. Recent developments have shown
that transesophageal ultrasound guided fine needle aspiration (EUS-FNA) and
endobronchial ultrasound guided transbronchial fine needle aspiration (EBUS-
TBNA) areminimally invasive diagnostic and staging procedures that have shown to
be highly sensitive and accurate. Although several studies have shown that these
cytological samples allow for reliable diagnosis and sub classification of non-small
cell lung cancer, cytological samples for molecular analysis are not yet routinely
used. In this paperwe review the current literature regarding the results of molecular
analysis of samples obtained by EUS-FNA and/or EBUS-TBNA, focusing on the
targets for currently available treatments of non-small cell lung cancer like epider-
mal growth factor receptor (EGFR), Kirsten rat sarcoma oncogene (KRAS) and
Echinoderm microtubule-associated protein-like 4 gene anaplastic lymphoma
kinase gene translocation (EML4-ALK). We conclude that the cytological samples
obtained by endosonography guided fine needle aspirations (EUS and EBUS) are
highly accurate formolecular analysis. This analysis can be performed reliably in the
vast majority of patients in daily practice.
Introduction
On the global scale lung cancer is the most commonly diag-
nosed cancer as well as the leading cause of cancer death in
males.1,2 Among females, it is the fourth most commonly
diagnosed cancer and the second leading cause of cancer
death.1,2 The five year survival rate of the various types of lung
cancer for bothEurope and theUnited States is approximately
16% and did not significantly improve in the last decade,
despite the emergence of new diagnostic and therapeutic
developments. Following the changes in tobacco use, the
incidence of lung cancer is ever increasing in a number of
countries, including China.2,3 This trend is attributable to an
increase in the incidence of lung cancer in women. Further-
more, adenocarcinoma has become the most frequent histo-
logical subtype of non-small cell lung cancer (NSCLC).4 In
general, these adenocarcinomas arise in more peripherally
located parts of the lung that are more difficult to reach for
diagnosis.As a result, in clinical practice the diagnosis of lung
cancer is often based on cytological specimens.Several studies
have shown that these cytological samples allow for reliable
diagnosis and sub classification of NSCLC.5–9
Cytological samples are increasingly obtained by
ultrasound-guided techniques with fine needle aspirations.
Recent developments have shown that transesophageal
ultrasound guided fine needle aspiration (EUS-FNA) and
endobronchial ultrasound guided transbronchial fine needle
aspiration (EBUS-TBNA) are minimally invasive diagnostic
and staging procedures which have shown to be highly sensi-
tive and accurate. Indications, technique and diagnostic
results have been extensively reviewed in this journal.10–16
These ultrasound-guided techniques allow safe cytological
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sampling of mediastinal lymph nodes and centrally located
intrapulmonary tumors or metastases in the upper
abdomen, including the adrenal gland.17,18 EUS-FNA and
EBUS have therefore been incorporated in the guidelines of
the European Society of Thoracic Surgeons (ESTS) and the
AmericanCollege of Chest Physicians (ACCP)19,20 and a com-
bination of these techniques has been shown to have a better
sensitivity and negative predictive value than cervical
mediastinoscopy.21–24
However, as opposed to cervical mediastinoscopy and
other surgical procedures, EUS-FNA and EBUS result in
cytological specimens with a limited amount of cancer cells
available for the increasing number of analytical tests. These
fine needle aspirates are preferably processed on slides for
rapid onsite evaluation (ROSE) and vials or tissue coagulum
clots for analysis of cell-blocks. Since these samples are often
the only available proof of lung cancer,molecular and genetic
analysis performed on cytological specimens is of increasing
interest, as it will allow for optimal and personalized therapy
choice.6,25–28
In this paper we review the current literature regarding the
results of molecular analysis of samples obtained by EUS-
FNA and/or EBUS-TBNA, focusing on targets for currently
available treatments of lung cancer. Furthermore we have
added practical information on the tissue handling proce-
dures we use in our endosonography center and pathology
department for cytology and tumor genetics.
EGFR
Determining the mutation status of the epidermal growth
factor receptor (EGFR) gene is of crucial importance to
adequately select patients with both early and advanced non-
small cell lung cancer (NSCLC) for targeted treatment with
tyrosine kinase inhibitors (TKI’s). EGFR mutation status is
also important to predict prognosis and response to EGFR
targeted treatment, possibly combined with radiotherapy,29,30
as well as systemic chemotherapy.31,32 Recently, a number of
studies reported on EGFR analysis in cellblock based cyto-
logical specimens from EBUS.33–35 In our study, bothmolecu-
lar analysis of EGFR andKRASmutationswere performed on
cytological material obtained by EUS or EBUS. We showed
that this was feasible and applicable in daily practice.Molecu-
lar analysis could be performed in 77% of the adenocarci-
noma samples, which was in agreement with the study by
Garcia-Olive et al.33,35 They showed that EGFR gene analysis
of the EBUS-TBNA sample was feasible in 26 (72.2%) out of
the 36 patients with lymph node metastasis using a similar
method.33,35 Nakajima et al. performed molecular analysis in
histological core biopsies obtained by EBUS in 43 of 46 lung
adenocarcinoma patients (94%).34 The percentage of EGFR
mutations found in the Spanish and Japanese studies men-
tioned above was 10% and 26%, as compared to 7.4% found
in our cohort.Thismight reflect a high percentage of cigarette
smoking patients in our predominantly male, Caucasian
group of patients. Recently, several studies have confirmed
these results in EBUS TBNA samples. In a study using
co-amplification at lower denaturation temperature-
polymerase chain reaction (COLD-PCR) technique Santis
et al. showed that molecular analysis of all EGFR target
sequences could be achieved in 126 of 132 (95.5%) of the
cases,with a prevalence of EGFRmutations of 10.5%.36 Billah
et al. analyzed 99 cases of EBUS-FNA specimens and found
96% to be adequate for analysis with a prevalence of EGFR
mutations of 29% in lung adenocarcinomas and 7% in non-
adenocarcinomas.37 And finally, in a large multigene analysis,
Nakajima et al. showed a high correlation between the EBUS
based analysis of EGFR, KRAS and tumor protein 53 (p53)
mutations and clinical outcome of treatment in a group of
153 patients.38
In conclusion, these studies uniformly show that EGFR
mutation status analysis can be performed adequately and
reliably in the vast majority of samples obtained by EUS or
EBUS guided fine needle aspirations. For this analysis obtain-
ing additional histological core samples is redundant andwill
only increase the risk of complications.8
KRAS
An increasing number of studies report combined molecular
testing for both Kirsten rat sarcoma oncogene (KRAS) and
EGFR mutations applied in all available cytological speci-
mens (both cell blocks and direct smears) as we reported first
in our study.35 In these specimens, the applicability in daily
routine analysis of EUS-FNA or EBUS guided fine needle
aspirationswas demonstrated.TheKRASmutational status is
of importance as KRAS is an important signaling step down-
stream of the EGF-receptor and mutations in KRAS relate to
resistance to EGFR targeted therapy, adjuvant chemo-
therapy.39,40 KRAS mutations may also be of relevance to
other downstream pathways like the PI3K/AKT pathway.30,41
The yield of KRAS mutation testing is generally equal to or
better than the results stated above for EGFR analysis. For
example, Santis et al. reported that KRAS status could be
obtained in 130 of 132 (98.4%) patients and foundmutations
in 19% of lung adenocarcinomas and 28% of NSCLC not
otherwise specified using a COLD-PCR technique for cyto-
logical material obtained by EBUS.36 Other studies have
reported approximately similar prevalence results ranging
from 3.5 to 38% KRAS mutation positive cases in different
study populations – in terms of race, gender and smoking
habits – and using DNA sequencing techniques.38,42 Because
KRAS and EGFR mutations can in general be regarded as
mutually exclusive, KRASmutation analysis might be used to
predict the absence of an EGFRmutation in samples inwhich
the EGFR analysis fails.43,44
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EML4-ALK
In NSCLC, EML4-ALK gene fusions occur as a result of small
inversionswithintheshortarmof chromosome2bywhichthe
Echinoderm microtubule-associated protein-like 4 (EML4)
gene and the anaplastic lymphoma kinase (ALK) are juxta-
posed.TheconstitutivelyactiveEML4-ALKfusionproteincan
be inhibited by the protein kinase inhibitor crizotinib.45–48
EML4-ALKrearrangements have been identified in 2 to 7%of
tumors using fluorescence in situ hybridization (FISH).Kwak
et al. published the first clinical study with ALK inhibition by
using the dual ALK and MET inhibitor crizotinib in patients
with ALK-fusion-positive advanced lung carcinoma.47 It is
important that adenocarcinomas that are negative for EGFR
andKRASmutations canbe screened for thepresenceof chro-
mosomal translocation,as theFDAhasapprovedCrizotinibas
the first drug successfully targeting this mechanism.46,48 Two
studies have shown that this analysis can be performed on
cytologicalmaterial obtainedbyEBUS.49,50Nakajimareported
EML4-ALK fusion in a case study with both FISH and reverse
transcriptase-polymerase chain reaction (rt-PCR) in an
EBUS-TBNA obtained cytological sample.49 Sakairi screened
EBUS samples of 109patients forALKpositivity using immu-
nohistochemical staining. In theALKpositive cases (6%) sub-
sequent FISH analysis was performed to detect ALK-
rearrangements,whichwere found in allALK-positive cases.50
Sequential testing for the different clinically relevantmolecu-
lar tests is reasonable and it is likely that themost cost-effective
strategy is to startwith eitherKRASand/orEGFRanalysis and
reserveALKanalysis forKRAS-andEGFR-negativespecimens
as,until now,onlyfivepatients havebeendiagnosedwithboth
EGFR mutation and loss of ALK translocation.51 However,
when treatment delay is of concern these analyses can be per-
formed simultaneously, provided that sufficient material for
molecular testing is obtainedby theEUS and/or EBUS.
Other targets, indications
and limitations
It is likely that in the near future new drugs targeting prolif-
eration mechanisms or pathways in lung cancer will become
available.26,43 Likely candidates are BRAF mutations, MET
amplification, PIK3CA mutations, HER2 mutations, AKT
mutations, MAP2K1 mutations and epithelial mesenchymal
transition (EMT) pathway transitions.43,52,53 Research activi-
ties are focusing on these candidate targets, but also on geno-
typing or sequencing multiple targets.44 The challenge will be
to refine the techniques to allow multiple testing in small
amounts of tumor tissue. In cytological specimens analysis of
total RNA,DNA and protein analysis have been reported.54
The abovementioned analytical procedures can also be
applied for restaging procedures in patients to detect acquired
resistance after treatment.55However, in linewith the findings
obtained in patients with stage III disease eligible for surgery
after induction (concomitant) chemoradiation therapy, one
must be aware of a lower negative predictive value and diag-
nostic accuracy of EUS and EBUS.56 Besides mediastinal
lymph node staging, EBUS and EUS guided analysis can be
used for accurate diagnosis of metastatic sites of non pulmo-
naryprimary tumors57,58 rendering the sameopportunities for
molecular analysis of the obtained cytological samples.
However, we need to stay aware of potential false positive
and negative results caused by regional differences and differ-
ent clonal or genetic tumor profiles, as has been reported in
studies targeting multiple sites of metastatic lung cancer.42,59
ROSE and tissue handling
RapidOn-Site cytological Evaluation (ROSE) of the EUS and
EBUS guided fine needle aspirations is effective in optimizing
the yield and efficiency of the EBUS-TBNA procedure and
increases the sensitivity of EUS-FNA from 80% to 88%
without increasing procedure length.60 Indeed, the additional
staff will increase the operational costs but recent data con-
vincingly demonstrates that aspirates performed with ROSE
optimize the utility of specimens obtained.61–63 Onsite feed-
back from the cytopathologist or cytology technician will not
only guide the endoscopist to repeat aspirations in order to
determine the correct diagnosis and stage, but also to obtain
sufficient material for cellblocks (or tissue clot coagulum) in
order tomaximize the yield for a complete cytological, immu-
nohistochemical andmolecular analysis in that patient.6,9,28,64
In our endosonography center we have performed over
1200 procedures. From each fine needle aspiration, direct
smears are made for Giemsa and Papanicolaou staining
(Fig 1). Giemsa stained smears are processed and analyzed
onsite for rapid onsite evaluation (ROSE) by a cytotechni-
cian. The remaining material is flushed from the needle into
fixative solution and is processed in cellblocks. Aspirations
are repeated until adequate and sufficientmaterial is obtained
for a diagnosis. When tumor tissue is found in ROSE, we
usually take one or two additional needle aspirations to allow
for a full immunohistochemical and molecular analysis from
cellblocks. From these cellblocks, 4 mm slides are cut for
Hematoxyline-eosine staining and immunocytochemistry.
For the molecular analysis of the tumor tissue and to mini-
mize the chance of false-negative results, both cellblocks and
smears are considered suitable for molecular analysis of
EGFR and KRAS when DNA can be isolated from regions
with >40% and >10% tumor cells, respectively.35,65 More sen-
sitive next-generation-techniques interrogating multiple
targets on minimal amounts of cells are currently being vali-
dated.Other studies have also used 40%37 or 70% tumor cells
as a cut-off value.53
ForDNA isolation from the cellblocks, the relevant regions
aremanuallymicrodissectedfromtwotothree20 mmsections
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using flanking hematoxyline-eosine stained slides as a refer-
ence. For DNA isolation from the smears, regions with suffi-
cient amount of tumor cells are scraped from the glass slides.
Relevant mutation analysis can subsequently be performed
using standard polymerase chain reaction (PCR) sequencing
techniques. In our institute, the average processing time for
EGFR sequencing is three days after arrival of thematerial.
Conclusion
Endosonography guided fine needle aspirations (EUS and
EBUS) and molecular analysis of the cytological material
obtained from these procedures have become an imperative
part of the diagnosis of lung cancer and choice of treatment in
daily practice. These diagnostic procedures are minimally
invasive and can be performed on an outpatient basis. The
cytological samples obtained by these procedures are highly
accurate for diagnostic purposes and sub classification of
NSCLC as well as sub typing of adenocarcinomas by using
additional immunohistochemical staining. This review also
shows that relevantmolecular analysis can be performed reli-
ably in thevastmajorityof patients.Althougharecent consen-
sus meeting regarding EGFR testing still advocates the
preferential use of histological samples,66 the evidence sup-
porting theuseof cytological samples formolecularanalyses is
increasing.
We strongly advocate ROSE and incorporation of trained
cytotechnicians or cytopathologists in the team as this allows
for immediate feedback on the amount and quality of the
obtained tissue sample. This team effort will further increase
the diagnostic yield and will help the endosonographer in
effectively sampling sufficient tumor cells in order to allow
for multiple molecular analyses.
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